A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
16 Nov 2023
Historique:
accepted: 18 08 2023
received: 18 04 2023
pubmed: 27 9 2023
medline: 27 9 2023
entrez: 27 9 2023
Statut: ppublish

Résumé

Cellular ontogeny and MLL breakpoint site influence the capacity of MLL-edited CD34+ hematopoietic cells to initiate and recapitulate infant patients' features in pro-B-cell acute lymphoblastic leukemia (B-ALL). We provide key insights into the leukemogenic determinants of MLL-AF4+ infant B-ALL.

Identifiants

pubmed: 37756522
pii: 498120
doi: 10.1182/blood.2023020858
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1752-1756

Informations de copyright

© 2023 by The American Society of Hematology.

Auteurs

Clara Bueno (C)

Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.
Spanish Collaborative Cancer Network, Carlos III Health Institute, Barcelona, Spain.

Raul Torres-Ruiz (R)

Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.
Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.
Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.

Talia Velasco-Hernandez (T)

Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.

Oscar Molina (O)

Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.

Paolo Petazzi (P)

Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.

Alba Martinez (A)

Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.

Virginia Rodriguez (V)

Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.

Meritxell Vinyoles (M)

Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.

Sandra Cantilena (S)

Development Biology Cancer Program, Cancer Section, UCLGOS Institute of Child Health, London, United Kingdom.

Owen Williams (O)

Development Biology Cancer Program, Cancer Section, UCLGOS Institute of Child Health, London, United Kingdom.

Nerea Vega-Garcia (N)

Hematology Laboratory, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
Developmental Tumors Biology Group, Leukemia, and other Pediatric Hemopathies, Pediatric Cancer Center Barcelona, Institut de Recerca, Hospital Sant Joan de Déu, Barcelona, Spain.

Sandra Rodriguez-Perales (S)

Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.

Jose C Segovia (JC)

Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.
Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.

Oscar Quintana-Bustamante (O)

Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.
Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.

Anindita Roy (A)

MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Department of Pediatrics and National Institute for Health and Care Research Oxford Biomedical Research Centre Hematology Theme, University of Oxford, Oxford, United Kingdom.

Claus Meyer (C)

Diagnostic Center of Acute Leukemia-Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany.

Rolf Marschalek (R)

Diagnostic Center of Acute Leukemia-Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany.

Alastair L Smith (AL)

MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Thomas A Milne (TA)

MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Mario F Fraga (MF)

Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.
Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center, El Entrego, Spain.
Health Research Institute of Asturias, Institute of Oncology of Asturias and Department of Organisms and Systems Biology, University of Oviedo, Oviedo, Spain.

Juan Ramón Tejedor (JR)

Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.
Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center, El Entrego, Spain.
Health Research Institute of Asturias, Institute of Oncology of Asturias and Department of Organisms and Systems Biology, University of Oviedo, Oviedo, Spain.

Pablo Menéndez (P)

Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.
Spanish Collaborative Cancer Network, Carlos III Health Institute, Barcelona, Spain.
Department of Biomedicine, University of Barcelona, Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.

Classifications MeSH